Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

기사 요약

The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.